Seedlabs
Source research

Feasibility, Safety, and Preliminary Efficacy of Very Low-Volume Interval Training in Advanced Cancer Patients

Dejan Reljic, Hans Joachim Herrmann, BENEDIKT JAKOBS, Walburga Dieterich, Dimitrios Mougiakakos, Markus Friedrich Neurath et al. · 2022 · 22 citationsRead the paper

PURPOSE: High-intensity interval training (HIIT) has been shown to improve cardiorespiratory fitness (CRF) and health-related outcomes in various chronic diseases, including cancer. However, data on feasibility and efficacy of HIIT in advanced cancer patients are still sparse, presumably because of safety concerns, like suspected immunosuppression after vigorous exercise. This randomized, sham-intervention controlled study aimed to investigate feasibility, safety, and preliminary efficacy of very low-volume HIIT (LOW-HIIT) in advanced cancer patients. METHODS: Twenty-seven patients (55.4 ± 13.2 yr) with different advanced cancers (Union for International Cancer Control [UICC] III/IV) were randomly allocated to LOW-HIIT ( n = 13), consisting of 5 × 1 min cycle ergometer intervals (14 min per session total duration) at 80% to 95% HR peak (two sessions per week for 12 wk), or a sham intervention ( n = 14) performing light physical mobilization exercises (SHAM). Primary outcomes were attrition and attendance rates, with values of ≤25% and ≥80%, respectively, considered acceptable. Secondary outcomes were safety, protocol fidelity, physiological (including CRF measures) and patient-reported outcomes (including fatigue and quality of life). RESULTS: One of 13 patients (8%) receiving LOW-HIIT dropped out. Mean attendance rate was ~93%. The prescribed minimum exercise intensity was consistently reached by all patients. Low-volume HIIT was well tolerated and not associated with any serious adverse event nor with increased infection susceptibility. There were no biochemical signs of acute immunosuppression after LOW-HIIT. Contrarily, differentiation and degranulation of natural killer cells was acutely increased postexercise. Low-volume HIIT improved CRF measures including peak oxygen uptake, self-reported fatigue, physical, and social functioning. No significant changes occurred in the SHAM group. CONCLUSIONS: Low-volume HIIT can be regarded as feasible and safe in advanced cancer patients. Our preliminary data indicate favorable acute effects on NK-cells and beneficial chronic adaptations in CRF, fatigue, and aspects of quality of life.

What the full text shows

Working prototype
  • LOW-HIIT improved self-reported social functioning. — +28 points (95% CI, 12–44 points) (12-week intervention in advanced cancer patients)
  • LOW-HIIT improved self-reported physical functioning. — +8 points (95% CI, 1–15 points) (12-week intervention in advanced cancer patients)
  • LOW-HIIT reduced self-reported fatigue. — +7 points (95% CI, 1–13 points) on FACIT scale (12-week intervention in advanced cancer patients)
  • High protocol adherence and feasibility. — ~93% attendance rate; 8% attrition rate (LOW-HIIT group)
  • Acute increase in NK cell activity post-exercise. — Increased differentiation (CD56 dim subset) and degranulation (60 min post-exercise)
  • Safety profile showed no serious adverse events. — 0 grade 3+ adverse events (LOW-HIIT group)
Setup
27 patients with advanced cancer (UICC III/IV), aged 55.4 ± 13.2 years.
How
A 12-week randomized, sham-controlled study where patients performed either LOW-HIIT (5 x 1 min intervals at 80-95% HR peak, 2x/week) or light mobilization exercises. Outcomes were measured via blood markers, cardiorespiratory fitness tests, and validated patient-reported questionnaires.
Limitations
Small sample size (pilot study) · Lack of formal sample size calculations · Short duration (12 weeks)

Summarized by Gemma 4 from the open-access full text · 11 Oct 2026. Read it